While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs ...

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...

Health policy scholar Paul Ginsburg joins the "First Opinion Podcast" to discus Medicare policy and the election.

Mark Cuban is a man on a mission — to disrupt the pharmaceutical industry.

Congress is facing a slew of expiring Medicare policies, and the end of Trump's tax cuts and Biden's extra ACA subsidies.

Opinion: More than $55 billion in opioid settlement money has flowed into state, county, and city coffers. Much of it is at ...

New research calls into question the high-profile conclusion of the first major study to show a physician's race influences ...

Linda Barbour thought she was more interested in the Change Healthcare cyberattack than most. Having worked as a medical ...

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable ...

A new study shows that Americans are more supportive than ever of a robust drug-epidemic response and access to addiction ...

Michelle Tarver will be the new leader of the medical devices center at the Food and Drug Administration, according to an ...